Matrix metalloproteinases 2 and 9 in the cochlea: Expression and activity after aminoglycoside exposition

Neuroscience

Volumn 181, Issue , 2011, Pages 28-39

  Setz, C ^a   Brand, Y ^a   Radojevic, V ^a   Hanusek, C ^a   Mullen, P J ^a   Levano, S ^a   Listyo, A ^a   Bodmer, D ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Apoptosis; Extracellular matrix; Hair cell; Inner ear; Retina

Indexed keywords

GELATINASE A; GELATINASE B; GENTAMICIN; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA;

AGE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DEATH; CELL SURVIVAL; COCHLEA; CONTROLLED STUDY; CORTI ORGAN; DRUG EXPOSURE; ENZYME ACTIVITY; HAIR CELL; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RAT; SPIRAL GANGLION; STRIA VASCULARIS; UPREGULATION;

AMINOGLYCOSIDES; ANIMALS; ANIMALS, NEWBORN; COCHLEA; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; NEUROTOXINS; ORGAN CULTURE TECHNIQUES; RATS; RATS, WISTAR;

EID: 79953715622     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.02.043     Document Type: Article

References (34)

1. Agapova O.A., Ricard C.S., Salvador-Silva M., Hernandez M.R. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human optic nerve head astrocytes. Glia 2001, 33:205-216.
2. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
3. Cauwe B., Van den Steen P.E., Opdenakker G. The biochemical, biological, and pathological kaleidoscope of cell surface substrates processed by matrix metalloproteinases. Crit Rev Biochem Mol Biol 2007, 42:113-185.
4. Chang D.I., Hosomi N., Lucero J., Heo J.H., Abumiya T., Mazar A.P., del Zoppo G.J. Activation systems for latent matrix metalloproteinase-2 are upregulated immediately after focal cerebral ischemia. J Cereb Blood Flow Metab 2003, 23:1408-1419.
5. Chintala S.K., Zhang X., Austin J.S., Fini M.E. Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation. J Biol Chem 2002, 277:47461-47468.
6. Chintala S.K. The emerging role of proteases in retinal ganglion cell death. Exp Eye Res 2006, 82:5-12.
7. Cho Y., Gong T.W., Stöver T., Lomax M.I., Altschuler R.A. Gene expression profiles of the rat cochlea, cochlear nucleus, and inferior colliculus. J Assoc Res Otolaryngol 2002, 3:54-67.
8. Clark A.W., Krekoski C.A., Bou S.S., Chapman K.R., Edwards D.R. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett 1997, 238:53-56.
9. Crawford H.C., Matrisian L.M. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells. Enzyme Protein 1996, 49:20-37.
10. Gasche Y., Soccal P.M., Kanemitsu M., Copin J.C. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 2006, 11:1289-1301.
11. Gu Z., Kaul M., Yan B., Kridel S.J., Cui J., Strongin A., Smith J.W., Liddington R.C., Lipton S.A. S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 2002, 297:1186-1190.
12. Kleiner D.E., Stetler-Stevenson W.G. Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol 1993, 5:891-897.
13. Kundu S., Tyagi N., Sen U., Tyagi S.C. Matrix imbalance by inducing expression of metalloproteinase and oxidative stress in cochlea of hyperhomocysteinemic mice. Mol Cell Biochem 2009, 332:215-224.
14. Lautermann J., Dehne N., Schacht J., Jahnke K. Aminoglycoside- and cisplatin-ototoxicity: from basic science to clinics. Laryngorhinootologie 2004, 83:317-323.
15. Lee R., Kermani P., Teng K.K., Hempstead B.L. Regulation of cell survival by secreted proneurotrophins. Science 2001, 294:1945-1948.
16. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays 1992, 14:455-463.
17. Meli D.N., Christen S., Leib S.L. Matrix metalloproteinase-9 in pneumococcal meningitis: activation via an oxidative pathway. J Infect Dis 2003, 187:1411-1415.
18. Murphy G., Docherty A.J. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol 1992, 7:120-125.
19. Nagy I., Monge A., Albinger-Hegyi A., Schmid S., Bodmer D. NF-kappaB is required for survival of immature auditory hair cells in vitro. J Assoc Res Otolaryngol 2005, 6:260-268.
20. Pei P., Horan M.P., Hille R., Hemann C.F., Schwendeman S.P., Mallery S.R. Reduced nonprotein thiols inhibit activation and function of MMP-9: implications for chemoprevention. Free Radic Biol Med 2006, 41:1315-1324.
21. Pirvola U., Xing-Qun L., Virkkala J., Saarma M., Murakata C., Camoratto A.M., Camoratto A.M., Walton K.M., Ylikoski J. Rescue of hearing, auditory hair cells, and neurons by CEP-1347/KT7515, an inhibitor of c-Jun N-terminal kinase activation. J Neurosci 2000, 20:43-50.
22. Reuter A., Nestl A., Zwacka R.M., Tuckermann J., Waldherr R., Wagner E.M., Höyhtyä M., Meyer zum Gottesberge A.M., Angel P., Weiher H. Expression of the recessive glomerulosclerosis gene Mpv17 regulates MMP-2 expression in fibroblasts, the kidney, and the inner ear of mice. Mol Biol Cell 1998, 9:1675-1682.
23. Rosenberg G.A. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009, 8:205-216.
24. Rosenberg G.A. Matrix metalloproteinases in neuroinflammation. Glia 2002, 39:279-291.
25. Rybak L.P., Whitworth C.A. Ototoxicity: therapeutic opportunities. Drug Discov Today 2005, 10:1313-1321.
26. Schönbeck U., Mach F., Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol 1998, 161:3340-3346.
27. Sternlicht M.D., Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
28. Stetler-Stevenson W.G., Liotta L.A., Kleiner D.E. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993, 7:1434-1441.
29. Webber C.A., Hocking J.C., Yong V.W., Stange C.L., McFarlane S. Metalloproteases and guidance of retinal ganglion axons in the developing visual system. J Neurosci 2002, 22:8091-8100.
30. Woo M.S., Park J.S., Choi I.Y., Kim W.K., Kim H.S. Inhibition of MMP-3 or -9 suppresses lipopolysaccharide-induced expression of proinflammatory cytokines and iNOS in microglia. J Neurochem 2008, 106:770-780.
31. Yang Y., Estrada E.Y., Thompson J.F., Liu W., Rosemberg G.A. Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat. J Cereb Blood Flow Metab 2007, 27:697-709.
32. Yong V.W., Power C., Forsyth P., Edwards D.R. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2001, 2:502-511.
33. Yu M., Sato H., Seiki M., Spiegel S., Thompson E.W. Calcium influx inhibits MT1-MMP processing and blocks MMP-2 activation. FEBS Lett 1997, 412:568-572.
34. Zhang X., Chintala S.K. Influence of interleukin-1 beta induction and mitogen-activated protein kinase phosphorylation on optic nerve ligation-induced matrix metalloproteinase-9 activation in the retina. Exp Eye Res 2004, 78:849-860.